Skip to content

Effects of Pilates Method and Aerobic Training in Hypertensive Subjects

Effects of Pilates Method and Aerobic Training in Hypertensive Subjects: a Randomized Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03214016
Enrollment
30
Registered
2017-07-11
Start date
2017-08-20
Completion date
2018-08-31
Last updated
2020-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Pilates Training, Aerobic Exercises, Hypertension, Clinical trial

Brief summary

This study evaluates the effects of Pilates method and aerobic training in hypertensive subjects. Half of participants will be trained with Pilates, while the other half will be trained with aerobic exercise during 8 weeks.

Interventions

OTHERAerobic Exercise

1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.

OTHERPilates

1 hour of Mat Pilates, 2 times a week, during 8 weeks.

Sponsors

Universidade Federal de Santa Maria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* subjects with high blood pressure controled by medication; * sedentary.

Exclusion criteria

* IMC≥30 kg/m² * using beta blockers * smokers or that interrupted the routine less than 6 months * musculoskeletal diseases in evolution or with current symptomatic * rheumatological diseases * other cardiovascular disease * renal disease due to hypertension * endocrine, neurological, oncological, immunological, hematological and psychiatric diseases.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline casual systolic blood pressure at 8 weeksbaseline and 8 weeksIt will be evaluated with oscillometric method of measuring blood pressure with an automated cuff.
Change from baseline 24-hour systolic blood pressure at 8 weeksbaseline and 8 weeksIt will be evaluated by 24-hour ambulatory BP monitoring (ABPM)

Secondary

MeasureTime frameDescription
Diastolic and mean blood pressurebaseline and 8 weeksIt will be evaluated by 24-hour ambulatory BP monitoring (ABPM)
Functional capacitybaseline and 8 weeksEvaluate by Six-Minute Walk Test (6MWT)
Respiratory muscle strengthbaseline and 8 weeksThe maximal inspiratory and expiratory pressures will be evaluated with manovacuometer
Muscle strengthbaseline and 8 weeksThe muscles (quadriceps, gastrocnemius, abdominal and spine extensors) will be evaluated with dynamometer.
Flexibilitybaseline and 8 weeksIt will be evaluated by bank of Wells test.
Body Mass Indexbaseline and 8 weeksIt will be calculated as weight (kg) divided by height squared.
Oxidative damagebaseline and 8 weeksIt will be evaluated by advanced oxidation protein products (AOPP)
Casual diastolic blood pressurebaseline and 8 weeksIt will be evaluated with oscillometric method of measuring blood pressure with an automated cuff.
Lipid profilebaseline and 8 weeksBy blood analysis (LDL, HDL, total cholesterol, glucose and triglycerides).
Endothelial functionbaseline and 8 weeksBy blood analysis (Nitrite measurement/NOx).
Inflammationbaseline and 8 weeksIt will be evaluated by C-reactive protein in blood analysis
Creatininebaseline and 8 weeksBy blood analysis
Lactatebaselina and 8 weeksBy blood analysis
Creatine kinasebaseline and 8 weeksBy blood analysis
Questionnaire of Quality of lifebaseline and 8 weeksIt will be evaluated by Mini-questionnaire of Quality of Life in Hypertension (MINICHAL)
Antioxidant capacitybaseline and 8 weeksIt will be evaluated by total antioxidant capacity (TAC).
Heart rate variabilitybaseline and 8 weeksIt will be evaluated using a previously validated heart rate monitor Polar 810i, and the results will be analyzed in time- and frequency-domains.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026